Program
drospirenone
Also written as “15 mg E4/3 mg DRSP”, “Drospirenone” and “0.25mg DRSP / 0.5mg E2 (BAY86-4891)”.
Its studies are mostly in Hot Flashes · Bone Diseases, Metabolic · Contraception Behavior · Overweight · Hemorrhage, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 60 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Estetra | 60 open or running | phase 3since Jun 27, 2016 | Apr 15, 2016 | none ahead |
| Insud Pharma | 21 open or running | phase 4since Mar 22, 2022 | Mar 22, 2022 | Dec 2027phase 4 · NCT05303636 |
| Laboratories Leon Farma | 10 open or running | phase 3since Oct 6, 2014 | Oct 6, 2014 | none ahead |
Also a collaborator on its studies: chemo-research, novum, pra-health-sciences, chemo-france and quotient-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2005First study: phase 4 study in PostmenopauseNew to BayerBayer · NCT00185328 · 55 enrolled
- Jul 25, 2006Phase 3 study in Vasomotor SymptomsBayer · NCT00356447 · 249 enrolled · China
- Mar 9, 2007Phase 3 study in Hot FlashesBayer · NCT00446199 · 735 enrolled · United States
- Apr 17, 2007Phase 3 study in DysmenorrheaBayer · NCT00461305 · 420 enrolled · Japan
- Aug 29, 2007Phase 3 study in Hot FlashesBayer · NCT00522873 · 662 enrolled · United States, Argentina, Austria and more
- Apr 2, 2008Phase 2 study in Contraceptive, Oral, HormonalBayer · NCT00653614 · 635 enrolled · Germany
- Oct 6, 2014Laboratories Leon Farma's first study: phase 3 study in ContraceptionNew to Laboratories Leon FarmaLaboratories Leon Farma · NCT02269241 · 1,552 enrolled · United States
- Apr 15, 2016Estetra's first study: phase 1 study in ContraceptionNew to EstetraEstetra · NCT02852681 · 28 enrolled
- Jun 27, 20162 phase 3 studies in ContraceptionEstetra · NCT02817841, NCT02817828
- Oct 25, 2016Phase 2 study in ContraceptionEstetra · NCT02957630 · 101 enrolled · Netherlands
- Mar 21, 2017Phase 2 study in Prevention of PregnancyEstetra · NCT03091595 · 82 enrolled · Netherlands
- Apr 19, 2018Phase 1 study in ContraceptionEstetra · NCT03512860 · 24 enrolled · United Kingdom
- Mar 22, 2022Insud Pharma's first study: phase 4 study in Bone Diseases, MetabolicNew to Insud PharmaInsud Pharma · NCT05303636 · 1,536 enrolled · United States, Czechia, Poland
- Jun 30, 2022Phase 3 study in Contraception BehaviorInsud Pharma · NCT05461573 · 1,542 enrolled · United States, Canada
Ahead
- Dec 2027Primary completion: phase 4 study in Bone Diseases, MetabolicInsud Pharma · NCT05303636
TargetBeta
“Mineralocorticoid receptor antagonist; Progesterone receptor agonist”ChEMBL 37, by rule
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05461573Contraception Behavior · United States, Canada | 3 | Completed | Insud Pharma | Aug 5, 2024 | 1,542 |
| NCT05303636Bone Diseases, Metabolic · United States, Czechia, Poland | 4 | Active, not recruiting | Insud Pharma | Dec 2027 | 1,536 |
| NCT03512860Contraception · United Kingdom | 1 | Completed | Estetra | Oct 8, 2018 | 24 |
| NCT03091595Prevention of Pregnancy · Netherlands | 2 | Completed | Estetra | Jun 8, 2018 | 82 |
| NCT02957630Contraception · Netherlands | 2 | Completed | Estetra | Oct 9, 2017 | 101 |
| NCT02817841Contraception · United States, Canada | 3 | Completed | Estetra | Oct 16, 2018 | 2,148 |
| NCT02817828Contraception · Belgium | 3 | Completed | Estetra | Apr 26, 2018 | 1,577 |
| NCT02852681Contraception | 1 | Completed | Estetra | Oct 2015 | 28 |
| NCT02269241Contraception · United States | 3 | Completed | Laboratories Leon Farma | Oct 4, 2017 | 1,552 |
| NCT00653614Contraceptive, Oral, Hormonal · Germany | 2 | Completed | Bayer | Jun 2009 | 635 |
| NCT00522873Hot Flashes · United States, Argentina, Austria and more | 3 | Completed | Bayer | Aug 2009 | 662 |
| NCT00461305Dysmenorrhea · Japan | 3 | Completed | Bayer | Jan 2009 | 420 |
| NCT00446199Hot Flashes · United States | 3 | Completed | Bayer | Oct 2008 | 735 |
| NCT00356447Vasomotor Symptoms · China | 3 | Completed | Bayer | Oct 2007 | 249 |
| NCT00185328Postmenopause | 4 | Completed | Bayer | 55 |
How it is read
Names in the registry
- “15 mg E4/3 mg DRSP”, 5 entries
- “Drospirenone”, 2 entries
- “0.25mg DRSP / 0.5mg E2 (BAY86-4891)”, 2 entries
- “Estradiol/DRSP (Angeliq, BAY86-4891)”, 2 entries
- “drospirenone”, 1 entry
Conditions, from the studies’ own filings
- Hot Flashes, 2 studies
- Bone Diseases, Metabolic, 1 study
- Contraception Behavior, 1 study
- Overweight, 1 study
- Hemorrhage, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.